After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Mylan’s program offered EpiPens to schools for free or at a discounted rate, which in 2015 was a little more than $100.

The move, which brings blockbuster treatments Viagra and Lipitor under one umbrella with Mylan's EpiPen, is part of a years-long effort by Pfizer to split into three parts - innovative medicines, ...

Mylan, the profiteering, tax-dodging drug company currently taking immense heat for jacking up the price of its Epipen by 500%, announced Thursday that it will help more patients cover their ...

The worst appears to be over for Mylan NV and its EpiPen controversy. It took a $465 million settlement with the U.S. Justice Department and a grilling from Congress for its chief executive ...

Mylan made $1.1 billion in revenue per year from EpiPen sales (though that may be decreasing with the introduction of new competition, including CVS’s generic auto-injector).

Mylan also said it would offer a $25 discount on the co-pays for buyers with health insurance, and a savings card good for a discount of up to $300 on deductible or co-pay expenses for the branded ...

Mylan NV, whose price increases on its lifesaving EpiPen drug drew broad criticism this month, said Monday it would launch a half-priced generic version of the medicine—in effect, competing ...

Mylan NV said on Thursday it would reduce the out-of-pocket costs of its emergency EpiPen allergy injection for some patients amid a wave of criticism from lawmakers and the public over the ...

Mylan NV is poised to lose its hostile bid for Perrigo Co., people familiar with the matter said, a rare outcome in one of the bitterest takeover battles in decades.

Mylan shares were up more than 12 percent, at $20.78. Follow Michael J. de la Merced and Katie Thomas on Twitter: @m_delamerced and @katie_thomas.